Genotype analysis of the human endostatin variant p.D104N in benign and malignant adrenocortical tumors
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.67, n.2, p.95-98, 2012
Resumo
OBJECTIVE: Endostatin is a potent endogenous inhibitor of angiogenesis. It is derived from the proteolytic cleavage of collagen XVIII, which is encoded by the COL18A1 gene. A polymorphic COL18A1 allele encoding the functional polymorphism p.D104N impairs the activity of endostatin, resulting in a decreased ability to inhibit angiogenesis. This polymorphism has been previously analyzed in many types of cancer and has been considered a phenotype modulator in some benign and malignant tumors. However, these data are controversial, and different results have been reported for the same tumor types, such as prostate and breast cancer. The purpose of this study was to genotype the p.D104N variant in a cohort of pediatric and adult patients with adrenocortical tumors and to determine its possible association with the biological behavior of adrenocortical tumors. METHODS: DNA samples were obtained from 38 pediatric and 56 adult patients (0.6-75 yrs) with adrenocortical tumors. The DNA samples were obtained from peripheral blood, frozen tissue or paraffin-embedded tumor blocks when blood samples or fresh frozen tissue samples were unavailable. Restriction fragment length polymorphism analysis was used to genotype the patients and 150 controls. The potential associations of the p.D104N polymorphism with clinical and histopathological features and oncologic outcome (age of onset, tumor size, malignant tumor behavior, and clinical syndrome) were analyzed. RESULTS: Both the patient group and the control group were in Hardy-Weinberg equilibrium. The frequencies of the p.D104N polymorphism in the patient group were 81.9% (DD), 15.9% (DN) and 2.2% (NN). In the controls, these frequencies were 80.6%, 17.3% and 2.0%, respectively. We did not observe any association of this variant with clinical or histopathological features or oncologic outcome in our cohort of pediatric and adult patients with adrenocortical tumors.
Palavras-chave
Endostatin, Angiogenesis, p.D104N polymorphism, Adrenocortical tumor
Referências
- Balasubramanian SP, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-107
- Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126
- CHANG JG, 1992, BLOOD, V80, P2092
- Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a
- FOLKMAN J, 1995, MOL MED, V1, P120
- Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404
- Iughetti P, 2001, CANCER RES, V61, P7375
- Liu Ta-Chih, 2003, Kaohsiung Journal of Medical Sciences, V19, P1
- Lourenco GJ, 2006, BREAST CANCER RES TR, V100, P335, DOI 10.1007/s10549-006-9259-z
- Macpherson GR, 2003, MOL CANCER THER, V2, P845
- Magennis DP, 1998, VIRCHOWS ARCH, V433, P69, DOI 10.1007/s004280050218
- Mundhenke C, 2001, CLIN CANCER RES, V7, P3366
- MURAKAMI T, 1989, ARCH HISTOL CYTOL, V52, P461, DOI 10.1679/aohc.52.461
- OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
- OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
- Ortega MM, 2003, LEUKEMIA RES, V27, P93, DOI 10.1016/S0145-2126(02)00218-7
- REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234
- Visakorpi T, 1999, ANN CHIR GYNAECOL FE, V88, P11
- Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97
- Zetter BR, 1998, ANNU REV MED, V49, P407